ATE240958T1 - Crf rezeptor-antagonisten und darauf bezogene methoden - Google Patents

Crf rezeptor-antagonisten und darauf bezogene methoden

Info

Publication number
ATE240958T1
ATE240958T1 AT99961675T AT99961675T ATE240958T1 AT E240958 T1 ATE240958 T1 AT E240958T1 AT 99961675 T AT99961675 T AT 99961675T AT 99961675 T AT99961675 T AT 99961675T AT E240958 T1 ATE240958 T1 AT E240958T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
related methods
crf receptor
compounds
treatment
Prior art date
Application number
AT99961675T
Other languages
English (en)
Inventor
Mustapha Haddach
Zhiqiang Guo
James R Mccarthy
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ATE240958T1 publication Critical patent/ATE240958T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
AT99961675T 1998-11-12 1999-11-12 Crf rezeptor-antagonisten und darauf bezogene methoden ATE240958T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19095898A 1998-11-12 1998-11-12
US40074499A 1999-09-21 1999-09-21
PCT/US1999/026984 WO2000027850A2 (en) 1998-11-12 1999-11-12 Crf receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE240958T1 true ATE240958T1 (de) 2003-06-15

Family

ID=26886600

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99961675T ATE240958T1 (de) 1998-11-12 1999-11-12 Crf rezeptor-antagonisten und darauf bezogene methoden

Country Status (19)

Country Link
US (3) US6348466B1 (de)
EP (1) EP1129096B1 (de)
JP (1) JP2002529469A (de)
KR (1) KR20010080402A (de)
CN (1) CN1178941C (de)
AT (1) ATE240958T1 (de)
AU (1) AU755997B2 (de)
BR (1) BR9915129A (de)
CA (1) CA2349904A1 (de)
DE (1) DE69908173T2 (de)
DK (1) DK1129096T3 (de)
ES (1) ES2196898T3 (de)
HK (1) HK1038925B (de)
IL (1) IL143105A0 (de)
NO (1) NO20012228L (de)
NZ (1) NZ511267A (de)
PT (1) PT1129096E (de)
TR (1) TR200102178T2 (de)
WO (1) WO2000027850A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398956A1 (en) * 2000-02-14 2001-08-16 Japan Tobacco Inc. A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
CA2407597A1 (en) * 2000-05-01 2001-11-08 Dupont Pharmaceuticals Company Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
US6541469B2 (en) 2000-05-18 2003-04-01 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
WO2001087886A1 (en) * 2000-05-18 2001-11-22 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
AU2002239589B2 (en) * 2000-11-03 2005-04-21 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
ATE526330T1 (de) 2000-12-28 2011-10-15 Ono Pharmaceutical Co Heterotrizyklische verbindungen als antagonisten des crf-rezeptors
EP1345938A1 (de) * 2000-12-28 2003-09-24 Neurocrine Biosciences, Inc. Tricyclische crf-rezeptor-antagonisten
TWI236908B (en) * 2001-04-30 2005-08-01 Glaxo Group Ltd Tricyclic pyrimidines compound
US7273871B2 (en) 2001-07-17 2007-09-25 Sb Pharmco Puerto Rico Inc. Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
GB0117395D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
CN100422186C (zh) 2003-06-25 2008-10-01 小野药品工业株式会社 吡唑并嘧啶化合物的甲磺酸盐、其结晶及其制备方法
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
ATE388150T1 (de) * 2003-12-22 2008-03-15 Sb Pharmco Inc Crf-rezeptorantagonisten und diese betreffende verfahren
EP1766014A4 (de) 2004-06-03 2008-12-10 Athlomics Pty Ltd Mittel und verfahren zur diagnose von stress
US7869958B2 (en) * 2004-08-09 2011-01-11 Research Development Foundation Structure-based modulators of B1 G-protein coupled receptors
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP2135608B8 (de) 2004-08-25 2012-03-21 Ardea Biosciences, Inc. S-Triazolyl-alpha-Mercaptoacetanilide als Inhibitoren von HIV-Umkehrtranskriptase
BRPI0611455A2 (pt) 2005-05-05 2010-09-08 Ardea Biosciences Inc diaril-purinas, azapurinas e deazapurinas como inibidores não nucleosìdicos da transcriptase reversa para tratamento de hiv
US7595324B2 (en) 2006-11-09 2009-09-29 Ardea Biosciences, Inc. Substituted thieno[3,2-D]pyrimidines as HIV inhibitors
SI2217577T1 (sl) 2007-11-27 2014-11-28 Ardea Biosciences, Inc. Nove spojine in sestavki ter metode uporabe
CA2709176C (en) 2007-12-14 2013-02-05 Ardea Biosciences, Inc. Reverse transcriptase inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5013737A (en) * 1988-02-22 1991-05-07 American Cyanamid Company 2,4,8-Trisubstituted-3H,6H-1,4,5A,8A-tetraazaacenaphtylene-3,5-(4H)-diones and 2,4-8-trisubstituted-4,5-dihydro-5-thioxo-3H,6H-1,4,5A,8A-tetrazaacenaphthylen-3-ones
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
CA2150483C (en) 1992-12-17 1999-09-14 Pfizer Limited Pyrazoles and pyrazolopyrimidines
EP0674641B1 (de) 1992-12-17 1999-03-03 Pfizer Inc. Pyrrolopyrimidine als crf antagonisten
RU2130453C1 (ru) 1992-12-17 1999-05-20 Пфайзер Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, способ лечения, промежуточный продукт
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
JP3398152B2 (ja) 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
DE69510940T2 (de) * 1994-06-16 1999-11-11 Pfizer Pyrazolo und pyrrolopyridine
DE69603240T2 (de) 1995-05-12 2000-01-05 Neurogen Corp Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
EP0901476A4 (de) 1996-03-26 2001-08-16 Du Pont Pharm Co Aryloxy- und arylthio-verknüpfte Pyridine und Pyrimidine, sowie Derivate davon
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
DK0915880T3 (da) 1996-07-24 2008-02-11 Bristol Myers Squibb Pharma Co Azolotriaziner og pyrimidiner
WO1998005661A1 (en) 1996-08-06 1998-02-12 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
HUP9903965A3 (en) * 1996-08-28 2002-02-28 Pfizer Substituted 6,5-hetero-bicyclic derivatives
US6159980A (en) 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands

Also Published As

Publication number Publication date
CN1178941C (zh) 2004-12-08
AU1819900A (en) 2000-05-29
WO2000027850A2 (en) 2000-05-18
PT1129096E (pt) 2003-09-30
JP2002529469A (ja) 2002-09-10
EP1129096B1 (de) 2003-05-21
DE69908173T2 (de) 2004-08-19
NO20012228D0 (no) 2001-05-04
US20020143008A1 (en) 2002-10-03
NZ511267A (en) 2002-12-20
EP1129096A2 (de) 2001-09-05
CN1326458A (zh) 2001-12-12
NO20012228L (no) 2001-05-04
US6723721B2 (en) 2004-04-20
KR20010080402A (ko) 2001-08-22
HK1038925B (zh) 2003-12-05
US6348466B1 (en) 2002-02-19
HK1038925A1 (en) 2002-04-04
IL143105A0 (en) 2002-04-21
AU755997B2 (en) 2003-01-02
WO2000027850A3 (en) 2000-08-03
US20040229879A1 (en) 2004-11-18
TR200102178T2 (tr) 2002-01-21
ES2196898T3 (es) 2003-12-16
BR9915129A (pt) 2001-08-07
CA2349904A1 (en) 2000-05-18
DE69908173D1 (de) 2003-06-26
DK1129096T3 (da) 2003-09-15

Similar Documents

Publication Publication Date Title
DE69908173D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DE69903333T2 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
SE9900100D0 (sv) New compounds
MA26846A1 (fr) Derives de 2,4-diaminopyrimidine utiles comme agents immunosuppresseurs.
BG105710A (en) 5ht1 antagonists for antidepressant therapy
BR0307156A (pt) Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos
MXPA03003714A (es) Antagonistas del receptor crf y metodos relacionados con los mismos.
NO20035148D0 (no) Tri- og tetra-aza-acenaftylenderivater som CRF- reseptorantagonister
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
EA200400822A1 (ru) Производные 3,4-дигидро-1h-изохинолин-2-ила
ATE250058T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
ATE260918T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
SE0103795D0 (sv) Compounds and method for the treatment of överactive bladder
EP1020467A4 (de) Amidverbindungen von n-acylaminosäuren und zwischenprodukte zu ihrer herstellung
EA200400764A1 (ru) 1,3-диарилпроп-2-ен-1-оны, композиция на их основе и применение
DE602004012318D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren
IT1317000B1 (it) Uso di composti di origine naturale ad attivita' antiangiogenica.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1129096

Country of ref document: EP

REN Ceased due to non-payment of the annual fee